Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-10-22

Clinical Trial Update: A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study assessing the effect of LY2216684 on the active metabolite of clopidogrel; completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CLOPIDOGREL (CLOPIDOGREL)
  • LY2216684

Snippet

Sponsor: Eli Lilly and Company | Conditions: Major Depressive Disorder | Phase 1 | Status: COMPLETED | Results posted: 2018-10-22